PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930115
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930115
Cancer Biomarkers Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of cancer biomarkers Market
The global cancer biomarkers market is a rapidly evolving segment of the oncology diagnostics and therapeutics landscape, playing a critical role in early cancer detection, treatment selection, and disease monitoring. Cancer biomarkers are biological molecules produced by tumors or generated by the body in response to cancer, enabling non-invasive and precise diagnosis through genomics and proteomics technologies.
Market Size and Forecast
According to Fortune Business Insights, the global cancer biomarkers market was valued at USD 42.87 billion in 2025. The market is projected to grow to USD 48.2 billion in 2026 and further reach USD 83.61 billion by 2034, registering a CAGR of 7.13% during the forecast period (2026-2034).
This sustained growth reflects increasing cancer prevalence, technological advancements in diagnostics, and expanding applications of biomarkers in personalized medicine and drug development.
Market Overview
Cancer biomarkers are extensively used across applications such as cancer diagnostics, prognostics, drug discovery and development, companion diagnostics, and personalized medicine. These biomarkers facilitate early disease detection, assess disease progression, and support treatment decision-making, significantly improving patient outcomes.
The increasing demand for precision oncology, along with the integration of biomarkers into clinical workflows, is strengthening their importance across healthcare systems globally. Furthermore, research collaborations between academic institutions and market players are accelerating biomarker discovery and validation.
Key Market Drivers
One of the primary drivers of the cancer biomarkers market is the rising global incidence of cancer, leading to growing demand for early diagnosis and targeted therapies. Biomarkers are increasingly used in disease risk assessment, therapy response evaluation, and companion diagnostics, fueling market expansion.
Additionally, strong research and development investments are driving innovation. According to the U.S. National Library of Medicine, approximately 1,515 cancer biomarkers are currently under clinical trials, highlighting a robust development pipeline that is expected to strengthen market growth during the forecast period.
Market Restraints
Despite strong growth prospects, the market faces challenges such as lack of reimbursement policies for biomarker testing in both emerging and developed economies. The high cost of cancer diagnosis and treatment, particularly in developing countries, limits patient access to biomarker testing and encourages reliance on lower-cost alternatives, restraining market growth to some extent.
Market Segmentation Analysis
By Cancer Type
Based on cancer type, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, and others.
The breast cancer segment dominated the market and is expected to hold a 32.59% share in 2026, driven by high disease prevalence, increased awareness, and ongoing research into novel biomarkers.
The lung cancer segment is anticipated to grow at a significant CAGR during the forecast period due to rising R&D investments and increasing lung cancer incidence globally.
By Biomarker Type
By biomarker type, the market includes PSA, HER-2, EGFR, KRAS, and others.
The HER-2 segment held the largest share, accounting for 33.34% in 2026, supported by its widespread use in breast cancer diagnosis. The HER-2 segment is projected to generate USD 14.25 billion in revenue by 2025.
Meanwhile, the EGFR biomarker segment is expected to grow at a faster pace, driven by increasing lung cancer prevalence.
By End User
Based on end user, the market is segmented into diagnostics & research laboratories, pharmaceutical & biotechnology companies, hospitals & specialty clinics, and others.
The diagnostics & research laboratories segment dominated the market with a 53.49% share in 2026, supported by rising test volumes and introduction of advanced diagnostic kits. Pharmaceutical and biotechnology companies are also witnessing growing demand due to increased use of biomarkers in drug discovery and development.
Regional Analysis
North America dominated the global cancer biomarkers market with a 35.94% share in 2025 and was valued at USD 17.29 billion in 2026. The U.S. market is projected to reach USD 15.03 billion by 2026, supported by advanced diagnostic technologies and strong R&D infrastructure.
Europe follows North America, with the UK projected to reach USD 2.19 billion and Germany USD 3.8 billion by 2026.
The Asia Pacific region is expected to grow at a significant CAGR, driven by increasing healthcare investments and adoption of biomarker-based diagnostics. The India market is projected to reach USD 1.35 billion by 2026, while Japan is expected to reach USD 3.40 billion by 2026.
Competitive Landscape
The cancer biomarkers market is semi-consolidated, with leading players including F. Hoffmann-La Roche Ltd., Abbott, Thermo Fisher Scientific, Bio-Rad Laboratories, and CENTOGENE N.V. Companies are focusing on new product launches, strategic collaborations, and regulatory approvals to strengthen their market position.
Conclusion
In conclusion, the global cancer biomarkers market is poised for strong growth from USD 42.87 billion in 2025 to USD 83.61 billion by 2034, driven by rising cancer prevalence, expanding applications in personalized medicine, and a strong pipeline of biomarker innovations. Despite reimbursement and cost-related challenges, continued advancements in diagnostics and increased research collaborations are expected to sustain long-term market expansion across developed and emerging regions.
Segmentation By Cancer Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Others
By Biomarker Type
- PSA
- HER-2
- EGFR
- KRAS
- Others
By End User
- Pharmaceutical & Biotechnology Companies
- Diagnostics & Research Laboratories
- Hospitals & Specialty Clinics
- Others
By Geography
- North America (the U.S. and Canada)
- Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)
- Latin America (Brazil, Mexico, and the Rest of Latin America)
- Middle East & Africa (South Africa, GCC and the Rest of Middle East & Africa)
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Prevalence/ Incidence, by Cancer Type, by Key Regional/ Countries
- 4.2. New Product Launches, by Key Market Players
- 4.3. Pipeline Analysis, Cancer Biomarkers
- 4.4. Key industry Developments - Mergers, Acquisitions and Partnerships
5. Global Cancer Biomarkers Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast - By Cancer Type
- 5.2.1. Lung Cancer
- 5.2.2. Breast Cancer
- 5.2.3. Colorectal Cancer
- 5.2.4. Prostate Cancer
- 5.2.5. Others
- 5.3. Market Analysis, Insights and Forecast - By Biomarker Type
- 5.3.1. PSA
- 5.3.2. HER-2
- 5.3.3. EGFR
- 5.3.4. KRAS
- 5.3.5. Others
- 5.4. Market Analysis, Insights and Forecast - By End User
- 5.4.1. Pharmaceutical & Biotechnology Companies
- 5.4.2. Diagnostics & Research Laboratories
- 5.4.3. Hospitals & Specialty Clinics
- 5.4.4. Others
- 5.5. Market Analysis, Insights and Forecast - By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America Cancer Biomarkers Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast - By Cancer Type
- 6.2.1. Lung Cancer
- 6.2.2. Breast Cancer
- 6.2.3. Colorectal Cancer
- 6.2.4. Prostate Cancer
- 6.2.5. Others
- 6.3. Market Analysis, Insights and Forecast - By Biomarker Type
- 6.3.1. PSA
- 6.3.2. HER-2
- 6.3.3. EGFR
- 6.3.4. KRAS
- 6.3.5. Others
- 6.4. Market Analysis, Insights and Forecast - By End User
- 6.4.1. Pharmaceutical & Biotechnology Companies
- 6.4.2. Diagnostics & Research Laboratories
- 6.4.3. Hospitals & Specialty Clinics
- 6.4.4. Others
- 6.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Cancer Biomarkers Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast - By Cancer Type
- 7.2.1. Lung Cancer
- 7.2.2. Breast Cancer
- 7.2.3. Colorectal Cancer
- 7.2.4. Prostate Cancer
- 7.2.5. Others
- 7.3. Market Analysis, Insights and Forecast - By Biomarker Type
- 7.3.1. PSA
- 7.3.2. HER-2
- 7.3.3. EGFR
- 7.3.4. KRAS
- 7.3.5. Others
- 7.4. Market Analysis, Insights and Forecast - By End User
- 7.4.1. Pharmaceutical & Biotechnology Companies
- 7.4.2. Diagnostics & Research Laboratories
- 7.4.3. Hospitals & Specialty Clinics
- 7.4.4. Others
- 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 7.5.1. U.K.
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Spain
- 7.5.5. Italy
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
8. Asia Pacific Cancer Biomarkers Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast - By Cancer Type
- 8.2.1. Lung Cancer
- 8.2.2. Breast Cancer
- 8.2.3. Colorectal Cancer
- 8.2.4. Prostate Cancer
- 8.2.5. Others
- 8.3. Market Analysis, Insights and Forecast - By Biomarker Type
- 8.3.1. PSA
- 8.3.2. HER-2
- 8.3.3. EGFR
- 8.3.4. KRAS
- 8.3.5. Others
- 8.4. Market Analysis, Insights and Forecast - By End User
- 8.4.1. Pharmaceutical & Biotechnology Companies
- 8.4.2. Diagnostics & Research Laboratories
- 8.4.3. Hospitals & Specialty Clinics
- 8.4.4. Others
- 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 8.5.1. Japan
- 8.5.2. China
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America Cancer Biomarkers Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast - By Cancer Type
- 9.2.1. Lung Cancer
- 9.2.2. Breast Cancer
- 9.2.3. Colorectal Cancer
- 9.2.4. Prostate Cancer
- 9.2.5. Others
- 9.3. Market Analysis, Insights and Forecast - By Biomarker Type
- 9.3.1. PSA
- 9.3.2. HER-2
- 9.3.3. EGFR
- 9.3.4. KRAS
- 9.3.5. Others
- 9.4. Market Analysis, Insights and Forecast - By End User
- 9.4.1. Pharmaceutical & Biotechnology Companies
- 9.4.2. Diagnostics & Research Laboratories
- 9.4.3. Hospitals & Specialty Clinics
- 9.4.4. Others
- 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
10. Middle East & Africa Cancer Biomarkers Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Key Findings / Summary
- 10.2. Market Analysis, Insights and Forecast - By Cancer Type
- 10.2.1. Lung Cancer
- 10.2.2. Breast Cancer
- 10.2.3. Colorectal Cancer
- 10.2.4. Prostate Cancer
- 10.2.5. Others
- 10.3. Market Analysis, Insights and Forecast - By Biomarker Type
- 10.3.1. PSA
- 10.3.2. HER-2
- 10.3.3. EGFR
- 10.3.4. KRAS
- 10.3.5. Others
- 10.4. Market Analysis, Insights and Forecast - By End User
- 10.4.1. Pharmaceutical & Biotechnology Companies
- 10.4.2. Diagnostics & Research Laboratories
- 10.4.3. Hospitals & Specialty Clinics
- 10.4.4. Others
- 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 10.5.1. GCC Countries
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Key Industry Developments
- 11.2. Global Market Share Analysis (2025)
- 11.3. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
- 11.3.1. F. Hoffmann-La Roche Ltd.
- 11.3.1.1. Overview,
- 11.3.1.2. Products & services,
- 11.3.1.3. SWOT analysis,
- 11.3.1.4. Recent developments,
- 11.3.1.5. strategies,
- 11.3.1.6. financials (based on availability)
- 11.3.2. Abbott
- 11.3.2.1. Overview,
- 11.3.2.2. Products & services,
- 11.3.2.3. SWOT analysis,
- 11.3.2.4. Recent developments,
- 11.3.2.5. strategies,
- 11.3.2.6. financials (based on availability)
- 11.3.3. CENTOGENE N.V.
- 11.3.3.1. Overview,
- 11.3.3.2. Products & services,
- 11.3.3.3. SWOT analysis,
- 11.3.3.4. Recent developments,
- 11.3.3.5. strategies,
- 11.3.3.6. financials (based on availability)
- 11.3.4. Bio-Rad Laboratories, Inc.
- 11.3.4.1. Overview,
- 11.3.4.2. Products & services,
- 11.3.4.3. SWOT analysis,
- 11.3.4.4. Recent developments,
- 11.3.4.5. strategies,
- 11.3.4.6. financials (based on availability)
- 11.3.5. CENTOGENE N.V.
- 11.3.5.1. Overview,
- 11.3.5.2. Products & services,
- 11.3.5.3. SWOT analysis,
- 11.3.5.4. Recent developments,
- 11.3.5.5. strategies,
- 11.3.5.6. financials (based on availability)
- 11.3.6. Axon Medchem
- 11.3.6.1. Overview,
- 11.3.6.2. Products & services,
- 11.3.6.3. SWOT analysis,
- 11.3.6.4. Recent developments,
- 11.3.6.5. strategies,
- 11.3.6.6. financials (based on availability)
- 11.3.7. Sino Biological Inc.
- 11.3.7.1. Overview,
- 11.3.7.2. Products & services,
- 11.3.7.3. SWOT analysis,
- 11.3.7.4. Recent developments,
- 11.3.7.5. strategies,
- 11.3.7.6. financials (based on availability)
- 11.3.8. R&D System
- 11.3.8.1. Overview,
- 11.3.8.2. Products & services,
- 11.3.8.3. SWOT analysis,
- 11.3.8.4. Recent developments,
- 11.3.8.5. strategies,
- 11.3.8.6. financials (based on availability)
- 11.3.9. BioVision Inc.
- 11.3.9.1. Overview,
- 11.3.9.2. Products & services,
- 11.3.9.3. SWOT analysis,
- 11.3.9.4. Recent developments,
- 11.3.9.5. strategies,
- 11.3.9.6. financials (based on availability)
- 11.3.10. Myriad RBM
- 11.3.10.1. Overview,
- 11.3.10.2. Products & services,
- 11.3.10.3. SWOT analysis,
- 11.3.10.4. Recent developments,
- 11.3.10.5. strategies,
- 11.3.10.6. financials (based on availability)
- 11.3.11. Other Prominent Players
- 11.3.11.1. Overview,
- 11.3.11.2. Products & services,
- 11.3.11.3. SWOT analysis,
- 11.3.11.4. Recent developments,
- 11.3.11.5. strategies,
- 11.3.11.6. financials (based on availability)
- 11.3.1. F. Hoffmann-La Roche Ltd.
12. Strategic Recommendation
List of Tables
- Table 1: Global Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
- Table 2: Global Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2021-2034
- Table 3: Global Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
- Table 4: Global Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
- Table 5: North America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
- Table 6: North America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2021-2034
- Table 7: North America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
- Table 8: North America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
- Table 9: Europe Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
- Table 10: Europe Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2021-2034
- Table 11: Europe Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
- Table 12: Europe Cancer Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
- Table 13: Asia Pacific Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
- Table 14: Asia Pacific Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2021-2034
- Table 15: Asia Pacific Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
- Table 16: Asia Pacific Cancer Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
- Table 17: Latin America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
- Table 18: Latin America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2021-2034
- Table 19: Latin America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
- Table 20: Latin America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
- Table 21: Middle East & Africa Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
- Table 22: Middle East & Africa Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2021-2034
- Table 23: Middle East & Africa Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
- Table 24: Middle East & Africa Cancer Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Cancer Biomarkers Market Revenue Breakdown (US$ Mn, %) by Region, 2025 & 2034
- Figure 2: Global Cancer Biomarkers Market Value Share (%), by Cancer Cancer Type, 2025 & 2034
- Figure 3: Global Cancer Biomarkers Market Forecast (US$ Mn), by Lung Cancer, 2021-2034
- Figure 4: Global Cancer Biomarkers Market Forecast (US$ Mn), by Breast Cancer, 2021-2034
- Figure 5: Global Cancer Biomarkers Market Forecast (US$ Mn), by Colorectal Cancer, 2021-2034
- Figure 6: Global Cancer Biomarkers Market Forecast (US$ Mn), by Prostate Cancer, 2021-2034
- Figure 7: Global Cancer Biomarkers Market Forecast (US$ Mn), by Others, 2021-2034
- Figure 8: Global Cancer Biomarkers Market Value Share (%), by Biomarker Type 2025 & 2034
- Figure 9: Global Cancer Biomarkers Market Forecast (US$ Mn), by PSA, 2021-2034
- Figure 10: Global Cancer Biomarkers Market Forecast (US$ Mn), by HER-2, 2021-2034
- Figure 11: Global Cancer Biomarkers Market Forecast (US$ Mn), by EGFR, 2021-2034
- Figure 12: Global Cancer Biomarkers Market Forecast (US$ Mn), by KRAS 2021-2034
- Figure 13: Global Cancer Biomarkers Market Forecast (US$ Mn), by Others, 2021-2034
- Figure 14: Global Cancer Biomarkers Market Value Share (%), by End User, 2025 & 2034
- Figure 15: Global Cancer Biomarkers Market Forecast (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2021-2034
- Figure 16: Global Cancer Biomarkers Market Forecast (US$ Mn), by Lung Cancer & Research Laboratories, 2021-2034
- Figure 17: Global Cancer Biomarkers Market Forecast (US$ Mn), by Hospitals & Speciality Clinics, 2021-2034
- Figure 18: Global Cancer Biomarkers Market Forecast (US$ Mn), by Others, 2021-2034
- Figure 19: Global Cancer Biomarkers Market Value (US$ Mn), by Region, 2025 & 2034
- Figure 20: North America Cancer Biomarkers Market Value (US$ Mn), by Cancer Cancer Type, 2025 & 2034
- Figure 21: North America Cancer Biomarkers Market Value Share (%), by Cancer Cancer Type, 2025
- Figure 22: North America Cancer Biomarkers Market Value (US$ Mn), by Biomarker Type, 2025 & 2034
- Figure 23: North America Cancer Biomarkers Market Value Share (%), by Biomarker Type, 2025
- Figure 24: North America Cancer Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
- Figure 25: North America Cancer Biomarkers Market Value Share (%), by End User, 2025
- Figure 26: North America Cancer Biomarkers Market Value (US$ Mn), By Country, 2025 & 2034
- Figure 27: North America Cancer Biomarkers Market Value Share (%), By Country, 2025
- Figure 28: Europe Cancer Biomarkers Market Value (US$ Mn), by Cancer Cancer Type, 2025 & 2034
- Figure 29: Europe Cancer Biomarkers Market Value Share (%), by Cancer Cancer Type, 2025
- Figure 30: Europe Cancer Biomarkers Market Value (US$ Mn), by Biomarker Type, 2025 & 2034
- Figure 31: Europe Cancer Biomarkers Market Value Share (%), by Biomarker Type, 2025
- Figure 32: Europe Cancer Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
- Figure 33: Europe Cancer Biomarkers Market Value Share (%), by End User, 2025
- Figure 34: Europe Cancer Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
- Figure 35: Europe Cancer Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
- Figure 36: Asia Pacific Cancer Biomarkers Market Value (US$ Mn), by Cancer Type, 2025 & 2034
- Figure 37: Asia Pacific Cancer Biomarkers Market Value Share (%), by Cancer Type, 2025
- Figure 38: Asia Pacific Cancer Biomarkers Market Value (US$ Mn), by Biomarker Type, 2025 & 2034
- Figure 39: Asia Pacific Cancer Biomarkers Market Value Share (%), by Biomarker Type, 2025
- Figure 40: Asia Pacific Cancer Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
- Figure 41: Asia Pacific Cancer Biomarkers Market Value Share (%), by End User, 2025
- Figure 42: Asia Pacific Cancer Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
- Figure 43: Asia Pacific Cancer Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
- Figure 44: Latin America Cancer Biomarkers Market Value (US$ Mn), by Cancer Type, 2025 & 2034
- Figure 45: Latin America Cancer Biomarkers Market Value Share (%), by Cancer Type, 2025
- Figure 46: Latin America Cancer Biomarkers Market Value (US$ Mn), by Biomarker Type, 2025 & 2034
- Figure 47: Latin America Cancer Biomarkers Market Value Share (%), by Biomarker Type, 2025
- Figure 48: Latin America Cancer Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
- Figure 49: Latin America Cancer Biomarkers Market Value Share (%), by End User, 2025
- Figure 50: Latin America Cancer Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
- Figure 51: Latin America Cancer Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
- Figure 52: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn), by Cancer Type, 2025 & 2034
- Figure 53: Middle East & Africa Cancer Biomarkers Market Value Share (%), by Cancer Type, 2025
- Figure 54: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn), by Biomarker Type, 2025 & 2034
- Figure 55: Middle East & Africa Cancer Biomarkers Market Value Share (%), by Biomarker Type, 2025
- Figure 56: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
- Figure 57: Middle East & Africa Cancer Biomarkers Market Value Share (%), by End User, 2025
- Figure 58: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
- Figure 59: Middle East & Africa Cancer Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
- Figure 60: Global Cancer Biomarkers Market Share (%), By Company, 2025
